Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study

References

• Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918–29.
   PubMed Web of Science ®Google Scholar
• Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363–80.
   PubMed Web of Science ®Google Scholar
• Chełstowska B, Barańczyk-Kuźma A, Kuźma-Kozakiewicz M. Dyslipidemia in patients with amyotrophic lateral sclerosis – a case control retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:195–205.
   PubMedGoogle Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004–9.
   PubMed Web of Science ®Google Scholar
• Pereira M, Gromicho M, Henriques A, Pronto-Laborinho AC, Grosskreutz J, Kuźma-Kozakiewicz M, et al. Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci. 2021;421:117292.
   PubMedGoogle Scholar
• Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31:236–44.
   PubMed Web of Science ®Google Scholar
• Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007;30:515–25.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32:649–61.
   PubMed Web of Science ®Google Scholar
• Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9:223–8.
   PubMed Web of Science ®Google Scholar
• Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011;300:23–7.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA’s adverse event reporting system. Drug Saf. 2018;41:403–13.
   PubMed Web of Science ®Google Scholar
• Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008;17:1068–76.
   PubMed Web of Science ®Google Scholar
• Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:1010–6.
   PubMed Web of Science ®Google Scholar
• Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273:81–3.
   PubMed Web of Science ®Google Scholar
• Cui C, Sun J, McKay KA, Ingre C, Fang F. Medication use and risk of amyotrophic lateral sclerosis – a systematic review. BMC Med. 2022;20:251.
   PubMed Web of Science ®Google Scholar
• Hu N, Ji H. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2022;43:5189–99.
   PubMed Web of Science ®Google Scholar
• Seelen M, van Doormaal PTC, Visser AE, Huisman MHB, Roozekrans MHJ, de Jong SW, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261:1949–56.
   PubMed Web of Science ®Google Scholar
• Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine. 2021;100:e26751.
   PubMed Web of Science ®Google Scholar
• Skajaa N, Bakos I, Horváth-Puhó E, Henderson VW, Lash TL, Sørensen HT. Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology. 2021;32:756–62.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Levy J, Dickerson AS, Paganoni S, Leventer-Roberts M. Statin medications and amyotrophic lateral sclerosis incidence and mortality. Am J Epidemiol. 2022;191:1248–57.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3:413–7.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Lash TL. Statins and amyotrophic lateral sclerosis – the level of evidence for an association. J Intern Med. 2009;266:520–6.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:241–5.
   PubMed Web of Science ®Google Scholar
• Nabizadeh F, Balabandian M, Sharafi AM, Ghaderi A, Rostami MR, Naser Moghadasi A. Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta Neurol Belg. 2022;122:979–86.
   PubMed Web of Science ®Google Scholar
• Schumacher J, Peter RS, Nagel G, Rothenbacher D, Rosenbohm A, Ludolph AC, et al. Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol. 2020;27:1405–14.
   PubMed Web of Science ®Google Scholar
• Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:538–46.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318:1925–6.
   PubMed Web of Science ®Google Scholar
• Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255.
   PubMed Web of Science ®Google Scholar
• Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR Statement. JAMA. 2021;326:1614–21.
   PubMed Web of Science ®Google Scholar
• Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun. 2019;10:1891.
   PubMed Web of Science ®Google Scholar
• Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062.
   PubMed Web of Science ®Google Scholar
• van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636–48.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481–7.
   PubMed Web of Science ®Google Scholar
• Chauquet S, Zhu Z, O'Donovan MC, Walters JTR, Wray NR, Shah S. Association of antihypertensive drug target genes with psychiatric disorders: a Mendelian randomization study. JAMA Psychiatry. 2021;78:623–31.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377–89.
   PubMed Web of Science ®Google Scholar
• Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93:75–81.
   PubMed Web of Science ®Google Scholar
• Xia K, Klose V, Högel J, Huang T, Zhang L, Dorst J, et al. Lipids and amyotrophic lateral sclerosis: a two-sample Mendelian randomization study. Eur J Neurol. 2023;30:1899–906.
   PubMed Web of Science ®Google Scholar
• Shao W, Li T, Wang Y, Shan S, Zhang H, Xue Y. Twenty-three medication-taking traits and stroke: a comprehensive Mendelian randomization study. Front Cardiovasc Med. 2023;10:1120721.
   PubMed Web of Science ®Google Scholar
• Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28:688–97.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12–23.
   PubMed Web of Science ®Google Scholar
• Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46:1–9.
   PubMed Web of Science ®Google Scholar
• Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today. 1998;40:975–90.
   Google Scholar
• Lee SH, Choi NY, Yu HJ, Park J, Choi H, Lee KY, et al. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol Neurobiol. 2016;53:695–705.
   PubMed Web of Science ®Google Scholar
• Li H, Kuwajima T, Oakley D, Nikulina E, Hou J, Yang WS, et al. Protein prenylation constitutes an endogenous brake on axonal growth. Cell Rep. 2016;16:545–58.
   PubMed Web of Science ®Google Scholar
• Kreple CJ, Searles Nielsen S, Schoch KM, Shen T, Shabsovich M, Song Y, et al. Protective effects of lovastatin in a population-based ALS study and mouse model. Ann Neurol. 2023;93:881–92.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318:947–56.
   PubMed Web of Science ®Google Scholar
• Wong JK, Roselle AK, Shue TM, Shimshak SJE, Beaty JM, Celestin NM, et al. Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis. Brain Commun. 2022;4:fcac207.
   PubMedGoogle Scholar